Coya Therapeutics (COYA) announced that Health Canada has accepted, without objection, the clinical trial application for COYA 302 for the treatment of amyotrophic lateral sclerosis. The CTA acceptance by Health Canada allows for activation of clinical sites in Canada, enhancing patient recruitment alongside the U.S. clinical sites.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COYA:
- Coya Therapeutics Receives $4.2M Milestone Payment
- Buy Rating for Coya: Phase 2 Trial Initiation and Financial Milestones Boost Prospects
- Coya Therapeutics, Inc.: Promising Advancements in ALS and FTD Treatment with COYA-302
- Coya Therapeutics commences dosing in ALSTARS trial
- Coya Therapeutics: Strong Financial Position and Upcoming Catalysts Support Buy Rating